Passive protection


Broadly neutralizing antibodies (bNAbs) can confer protection against HIV-1 infection in humanized mice and in primate models, but whether immunotherapy with a monoclonal bNAb can control HIV-1 in humans remains unclear. In Nature, Nussenzweig and colleagues describe a phase I clinical trial designed to elicit passive anti-viral protection by the potent… (More)
DOI: 10.1038/ni.3186